Cardiovascular risk assessment and treatment in systemic lupus erythematosus

With improved treatment modalities and survival rates, patients with systemic lupus erythematosus live longer and their co-morbidities have become more apparent. Of great concern is cardiovascular disease, which has become a leading cause of death. Lupus patients prematurely develop atherosclerosis,...

Full description

Saved in:
Bibliographic Details
Published inBest practice & research. Clinical rheumatology Vol. 23; no. 4; pp. 481 - 494
Main Authors Elliott, Jennifer R., MD, Manzi, Susan, MD, MPH
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 01.08.2009
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:With improved treatment modalities and survival rates, patients with systemic lupus erythematosus live longer and their co-morbidities have become more apparent. Of great concern is cardiovascular disease, which has become a leading cause of death. Lupus patients prematurely develop atherosclerosis, which likely arises from an interaction among traditional cardiovascular risk factors, factors specific to lupus itself and inflammatory mediators. Despite these findings, lupus patients are not always adequately evaluated for traditional risk factors, many of which are treatable and reversible. We propose that lupus patients be assessed and managed regarding cardiovascular risk factors in the same manner as patients with known cardiovascular disease. As a result, preventive cardiology should be considered an essential component of the care for patients with lupus.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1521-6942
1532-1770
DOI:10.1016/j.berh.2009.03.005